Biogen boosts the executive management team of its spin-off hemophilia company

The spin-off of Bioverativ is on track to be completed in early 2017.

“Biogen is committed to positioning Bioverativ for success as it prepares to carry forward our dedication to the hemophilia community,” remarked George A. Scangos, CEO of Biogen. “Rogerio and John will be instrumental players in that success, alongside the rest of the executive team.”

“Rogerio’s expertise in the industry and extensive knowledge of the rare disease space will be critical as we work to deliver transformative medicines to patients,” said John Cox, CEO of Bioverativ. “And, given John’s strong track record of fiscal and operational management across all of the major disciplines within finance, I am confident in his ability to lead our global finance organization and be an excellent representative for our shareholders.”

Dr Vivaldi has more than 20 years of experience in delivering orphan products to patients worldwide, most notably during his tenure at Genzyme, where he applied his medical and professional expertise to lead the company's rare disease business and earned a reputation as a passionate advocate for patients. Most recently, he served as chief commercial officer at Spark Therapeutics, a gene therapy company, and was co-founder, president and CEO of Minerva Neurosciences.

He received his medical degree from Universidade do Rio de Janeiro Medical School, and completed his residency in endocrinology at Universidade do Estado do Rio de Janeiro and his fellowship at Mount Sinai Hospital Center in New York in the department of genetics. He received his MBA degree from COPPEAD, Universidade Federal do Rio de Janeiro.

Dr Vivaldi will be responsible for building and leading all aspects of Bioverativ’s commercial organization, including oversight of sales and marketing for the franchise’s lead products, Eloctate and Alprolix, extended half-life therapies for the treatment of hemophilia A and hemophilia B, respectively. He will report to Bioverativ CEO John Cox.

“Bioverativ is a unique opportunity to join a new company with a strong commercial business, growing pipeline and an experienced team dedicated to delivering results for patients, providers and caregivers,” said Dr Vivaldi. “I am passionate about improving lives through innovative therapies and ardent patient advocacy, and believe Bioverativ shares this vision.”

Mr Greene joins Bioverativ from Willis Group, where he served as CFO, enhancing business analytics and company performance while helping to execute on an ambitious merger and acquisition program. Previously, he was CFO for HSBC Holdings, earning positions of increasing responsibility over 8 years with the company, including CFO for the Global Retail Bank and Wealth Management business. Earlier in his career, Mr Greene spent 12 years in various roles at General Electric. He earned his undergraduate degree from the State University of New York and an MBA from Northwestern University’s Kellogg School of Management.

“I am excited about the opportunity to apply my experience to a field that makes a meaningful difference in the lives of those it serves,” said Mr Greene. “I look forward to working with the Bioverativ leadership team to create a leading organization that I believe is well-positioned for growth based on world-class science and a focus on addressing serious unmet needs in the blood disorders community.”

Mr Greene will be responsible for all financial and fiscal management of Bioverativ’s operations, with oversight for the company’s finance, information technology and technical operations functions. He will also work closely with business development, and research and development to grow the business. He will also report to Mr Cox.